PACIFIC
Durvalumab Consolidation after Chemoradiotherapy in Stage III NSCLC
Doente / População Intervenção / Exposição Comparação Desfecho
In 713 patients with unresectable stage III NSCLC and no progression after concurrent chemoradiation, durvalumab consolidation for one year improved progression-free and overall survival compared with placebo.
N
713
Desenho
Double-blind RCT, 2:1 randomisation
Desfecho
PFS and OS (co-primary)
Relevância
2
ResultadoPFS 16.8 vs 5.6 months (HR 0.52). 5-yr OS 42.9% vs 33.4%; 5-yr PFS 33.1% vs 19.0%.
Antonia SJ, et al. N Engl J Med. 2017;377(20):1919-1929; Spigel DR, et al. J Clin Oncol. 2022;40(12):1301-1311. 10.1056/NEJMoa1709937
Discussão e crítica
Established the 'PACIFIC regimen' as global standard for unresectable stage III NSCLC. Excluded EGFR-mutated disease — separate evidence applies there.